SLN Stock Overview
Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
Silence Therapeutics plc Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$21.62 |
| 52 Week High | US$27.72 |
| 52 Week Low | US$4.84 |
| Beta | 1.4 |
| 1 Month Change | 0.14% |
| 3 Month Change | 13.25% |
| 1 Year Change | 229.07% |
| 3 Year Change | -17.13% |
| 5 Year Change | n/a |
| Change since IPO | 10.87% |
Recent News & Updates
Recent updates
Need To Know: Analysts Are Much More Bullish On Silence Therapeutics plc (NASDAQ:SLN) Revenues
Feb 07
Subdued Growth No Barrier To Silence Therapeutics plc (NASDAQ:SLN) With Shares Advancing 65%
Nov 27Silence Therapeutics wins FDA’s fast track status for blood cancer therapy
Sep 08Silence Therapeutics prices 5.95M ADSs at $9.50/share
Aug 12New finance chief for Silence Therapeutics
Jan 06Shareholder Returns
| SLN | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -1.8% | 0.4% | 1.0% |
| 1Y | 229.1% | 0.9% | 21.9% |
Return vs Industry: SLN exceeded the US Biotechs industry which returned 0.7% over the past year.
Return vs Market: SLN exceeded the US Market which returned 24.9% over the past year.
Price Volatility
| SLN volatility | |
|---|---|
| SLN Average Weekly Movement | 8.2% |
| Biotechs Industry Average Movement | 11.6% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.8% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: SLN has not had significant price volatility in the past 3 months.
Volatility Over Time: SLN's weekly volatility (8%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1994 | 109 | Craig Tooman | www.silence-therapeutics.com |
Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company’s mRNAi GalNAc Oligonucleotide Discovery platform consists of precision engineered product candidates designed to target specific disease-associated genes in the liver. The company develops Zerlasiran (SLN360), which is in phase 2 clinical trial for cardiovascular disease associated with elevated lipoprotein(a); and Divesiran (SLN124), an siRNA molecule that is in Phase I clinical trials for the treatment of genetic hematological conditions, including polycythemia vera.
Silence Therapeutics plc Fundamentals Summary
| SLN fundamental statistics | |
|---|---|
| Market cap | US$1.01b |
| Earnings (TTM) | -US$54.14m |
| Revenue (TTM) | US$31.75m |
31.7x
P/S Ratio-18.6x
P/E RatioIs SLN overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| SLN income statement (TTM) | |
|---|---|
| Revenue | UK£25.38m |
| Cost of Revenue | UK£10.32m |
| Gross Profit | UK£15.06m |
| Other Expenses | UK£58.32m |
| Earnings | -UK£43.27m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.93 |
| Gross Margin | 59.34% |
| Net Profit Margin | -170.51% |
| Debt/Equity Ratio | 0% |
How did SLN perform over the long term?
See historical performance and comparison